Sign In to Follow Application
View All Documents & Correspondence

Heparan Sulfate Having High 3 O Sulfation Rate Of Glucosamine Residues

Abstract: The present invention provides a novel sulfated polysaccharide having an anticoagulant activity. Specifically, the present invention provides the polysaccharide comprising a repetitive structure of a disaccharide unit composed of a hexuronic acid (HexA) residue and a a-D-glucosamine (GlcN) residue and having 13% or higher of a 3-0-sulfation rate in GlcN residues.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
20 July 2018
Publication Number
30/2018
Publication Type
INA
Invention Field
BIO-CHEMISTRY
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2022-11-16
Renewal Date

Applicants

AJINOMOTO CO., INC.
15-1, Kyobashi 1-chome, Chuo-ku, Tokyo 104-8315

Inventors

1. MORI, Kenichi
c/o Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681
2. TOKURA, Yuriko
c/o Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681
3. YAMAZAKI, Shunsuke
c/o Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681
4. SHIMIZU, Tomoko
c/o Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681
5. MIHARA, Yasuhiro
c/o Ajinomoto Co., Inc. 1-1, Suzuki-cho, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-8681

Claims

1. A polysaccharide having an anticoagulant activity, comprising a repetitive structure of a disaccharide unit shown in a following general formula (I): wherein Ri to R5 meet following conditions; Ri, R2, R4 and R5 each independently represent a hydrogen or a sulfate group; R3 represents a hydrogen, a sulfate group or an acetyl group; at least a part of R3 is a sulfate group; a rate of the sulfate group in R4 is 13% or more; and a rate of the sulfate group in R5 is 50% or more.

2. The polysaccharide according to claim 1, wherein a content rate of said disaccharide unit is 90% or more.

3. The polysaccharide according to claim 1 or 2, wherein 50% or more sugar chains in total number of sugar chains that constitute said polysaccharide are composed of a structure shown in a following general formula (II): wherein Ri to R5 are the same as Ri to R5 in said general formula (I); and n is 3 to 30 as an average value.

4. The polysaccharide according to any one of claims 1 to 3, wherein 50% or more sugar chains in total number of sugar chains that constitute said polysaccharide are composed of a structure shown in a following general formula (II): wherein Ri to R5 are the same as Ri to R5 in said general formula (I); and n is 3 to 15 as the average value.

5. The polysaccharide according to any one of claims 1 to 4, wherein an average number of linked sugar residues is 6 to 60.

6. The polysaccharide according to any one of claims 1 to 5, wherein an average number of linked sugar residues is 6 to 30.

7. The polysaccharide according to any one of claims 1 to 6, wherein a number average molecular weight measured by gel permeation chromatography using pullulan as a standard is 8000 to 60000.

8. The polysaccharide according to any one of claims 1 to 7, wherein a number average molecular weight measured by gel permeation chromatography using pullulan as a standard is 12000 to 40000.

9. The polysaccharide according to any one of claims 1 to 8, wherein a weight average molecular weight measured by gel permeation chromatography using pullulan as a standard is 10000 to 100000.

10. The polysaccharide according to any one of claims 1 to 9, wherein a weight average molecular weight measured by gel permeation chromatography using pullulan as a standard is 15000 to 50000.

11. The polysaccharide according to any one of claims 1 to 10, wherein a rate of iduronic acid residues in hexuronic acid residues in said disaccharide unit is 0% to 70%.

12. The polysaccharide according to any one of claims 1 to 11, wherein a rate of a sulfate group in Ri is 0% to 80%.

13. The polysaccharide according to any one of claims 1 to 12, wherein a rate of a sulfate group in Ri in a iduronic acid residues 0% to 100%.

14. The polysaccharide according to any one of claims 1 to 13, wherein a rate of a sulfate group in Ri in glucuronic acid residues 0% to 50%.

15. The polysaccharide according to any one of claims 1 to 14, wherein a rate of a sulfate group in R2 is less than 1%.

16. The polysaccharide according to any one of claims 1 to 15, wherein a rate of a sulfate group in R3 is 70% to 100%.

17. The polysaccharide according to any one of claims 1 to 16, wherein a rate of a acetyl group in R3 is 0 to 33%.

18. The polysaccharide according to any one of claims 1 to 17, wherein a rate of a sulfate group in R4 is 45% or less.

19. The polysaccharide according to any one of claims 1 to 18, wherein a rate of a sulfate group in R5 is 70% to 100%.

20. The polysaccharide according to any one of claims 1 to 19, comprising one or more disaccharide units selected from GlcA-GlcN(NS3S6S), GlcA(2S)-GlcN(NS6S), IdoA(2S)-GlcN(NS6S) , GlcA-GlcN(NS6S), IdoA(2S)-GlcN(NS), IdoA(2S)-GlcN(NS3S) , IdoA-GlcN(NS6S), and GlcA-GlcN(NS) at a total content rate of 50% or more.

21. The polysaccharide according to any one of claims 1 to 20, wherein a ratio of anti-factor Xa activity/anti-factor Ila activity is 1.5 or more.

22. The polysaccharide according to any one of claims 1 to 21, wherein a ratio (Mw/Mn) of a weight average molecular weight (Mw) to a number average molecular weight (Mn) measured by gel permeation chromatography using pullulan as a standard is 1.5 or less.

23. The polysaccharide according to any one of claims 1 to 22, which is a free form, or a pharmacologically acceptable salt, or a mixture thereof.

24. The polysaccharide according to any one of claims 1 to 23, which said salt is selected from an ammonium salt, a sodium salt, a lithium salt, and a calcium salt.

25. A pharmaceutical composition comprising the polysaccharide according to any one of claims 1 to 24.

26. The composition according to claim 25, which is used for prevention, amelioration and/or treatment of a symptom attributed to blood coagulation.

27. The composition according to claim 26, wherein said symptom is disseminated intravascular coagulation syndrome, thrombotic embolism, blood coagulation in artificial dialysis or blood coagulation in extracorporeal circulation.

Specification

WE CLAIM:
1. A polysaccharide having an anticoagulant activity,
comprising a repetitive structure of a disaccharide unit
shown in a following general formula (I):

wherein
Ri to R5 meet following conditions;
Ri, R2, R4 and R5 each independently represent a hydrogen or
a sulfate group;
R3 represents a hydrogen, a sulfate group or an acetyl
group;
at least a part of R3 is a sulfate group;
a rate of the sulfate group in R4 is 13% or more; and
a rate of the sulfate group in R5 is 50% or more.
2. The polysaccharide according to claim 1, wherein a content rate of said disaccharide unit is 90% or more.
3. The polysaccharide according to claim 1 or 2, wherein 50% or more sugar chains in total number of sugar chains that constitute said polysaccharide are composed of a structure shown in a following general formula (II):


wherein
Ri to R5 are the same as Ri to R5 in said general formula
(I); and
n is 3 to 30 as an average value.
4. The polysaccharide according to any one of claims 1 to 3, wherein 50% or more sugar chains in total number of sugar chains that constitute said polysaccharide are composed of a structure shown in a following general formula (II):

wherein
Ri to R5 are the same as Ri to R5 in said general formula
(I); and
n is 3 to 15 as the average value.

5. The polysaccharide according to any one of claims 1 to
4, wherein an average number of linked sugar residues is 6
to 60.
6. The polysaccharide according to any one of claims 1 to
5, wherein an average number of linked sugar residues is 6
to 30.
7. The polysaccharide according to any one of claims 1 to
6, wherein a number average molecular weight measured by
gel permeation chromatography using pullulan as a standard
is 8000 to 60000.
8. The polysaccharide according to any one of claims 1 to
7, wherein a number average molecular weight measured by
gel permeation chromatography using pullulan as a standard
is 12000 to 40000.
9. The polysaccharide according to any one of claims 1 to
8, wherein a weight average molecular weight measured by
gel permeation chromatography using pullulan as a standard
is 10000 to 100000.
10. The polysaccharide according to any one of claims 1 to
9, wherein a weight average molecular weight measured by
gel permeation chromatography using pullulan as a standard
is 15000 to 50000.
11. The polysaccharide according to any one of claims 1 to
10, wherein a rate of iduronic acid residues in hexuronic
acid residues in said disaccharide unit is 0% to 70%.

12. The polysaccharide according to any one of claims 1 to
11, wherein a rate of a sulfate group in Ri is 0% to 80%.
13. The polysaccharide according to any one of claims 1 to
12, wherein a rate of a sulfate group in Ri in a iduronic
acid residues 0% to 100%.
14. The polysaccharide according to any one of claims 1 to
13, wherein a rate of a sulfate group in Ri in glucuronic
acid residues 0% to 50%.
15. The polysaccharide according to any one of claims 1 to
14, wherein a rate of a sulfate group in R2 is less than 1%.
16. The polysaccharide according to any one of claims 1 to
15, wherein a rate of a sulfate group in R3 is 70% to 100%.
17. The polysaccharide according to any one of claims 1 to
16, wherein a rate of a acetyl group in R3 is 0 to 33%.
18. The polysaccharide according to any one of claims 1 to
17, wherein a rate of a sulfate group in R4 is 45% or less.
19. The polysaccharide according to any one of claims 1 to
18, wherein a rate of a sulfate group in R5 is 70% to 100%.
20. The polysaccharide according to any one of claims 1 to
19, comprising one or more disaccharide units selected from
GlcA-GlcN(NS3S6S), GlcA(2S)-GlcN(NS6S), IdoA(2S)-GlcN(NS6S) ,
GlcA-GlcN(NS6S), IdoA(2S)-GlcN(NS), IdoA(2S)-GlcN(NS3S) ,
IdoA-GlcN(NS6S), and GlcA-GlcN(NS) at a total content rate
of 50% or more.

21. The polysaccharide according to any one of claims 1 to
20, wherein a ratio of anti-factor Xa activity/anti-factor
Ila activity is 1.5 or more.
22. The polysaccharide according to any one of claims 1 to
21, wherein a ratio (Mw/Mn) of a weight average molecular
weight (Mw) to a number average molecular weight (Mn)
measured by gel permeation chromatography using pullulan as
a standard is 1.5 or less.
23. The polysaccharide according to any one of claims 1 to
22, which is a free form, or a pharmacologically acceptable
salt, or a mixture thereof.
24. The polysaccharide according to any one of claims 1 to
23, which said salt is selected from an ammonium salt, a
sodium salt, a lithium salt, and a calcium salt.
25. A pharmaceutical composition comprising the polysaccharide according to any one of claims 1 to 24.
26. The composition according to claim 25, which is used for prevention, amelioration and/or treatment of a symptom attributed to blood coagulation.
27. The composition according to claim 26, wherein said symptom is disseminated intravascular coagulation syndrome, thrombotic embolism, blood coagulation in artificial dialysis or blood coagulation in extracorporeal circulation.

Documents

Application Documents

# Name Date
1 201847027122-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [20-07-2018(online)].pdf 2018-07-20
2 201847027122-STATEMENT OF UNDERTAKING (FORM 3) [20-07-2018(online)].pdf 2018-07-20
3 201847027122-SEQUENCE LISTING(PDF) [20-07-2018(online)].pdf 2018-07-20
4 201847027122-SEQUENCE LISTING [20-07-2018(online)].txt 2018-07-20
5 201847027122-PROOF OF RIGHT [20-07-2018(online)].pdf 2018-07-20
6 201847027122-PRIORITY DOCUMENTS [20-07-2018(online)].pdf 2018-07-20
7 201847027122-POWER OF AUTHORITY [20-07-2018(online)].pdf 2018-07-20
8 201847027122-FORM 1 [20-07-2018(online)].pdf 2018-07-20
9 201847027122-DECLARATION OF INVENTORSHIP (FORM 5) [20-07-2018(online)].pdf 2018-07-20
10 201847027122-COMPLETE SPECIFICATION [20-07-2018(online)].pdf 2018-07-20
11 201847027122-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [20-07-2018(online)].pdf 2018-07-20
12 Correspondence by Agent_Form 1_02-08-2018.pdf 2018-08-02
13 201847027122-FORM 3 [20-11-2018(online)].pdf 2018-11-20
14 201847027122-FORM 3 [30-08-2019(online)].pdf 2019-08-30
15 201847027122-FORM 18 [30-08-2019(online)].pdf 2019-08-30
16 201847027122-FORM 4(ii) [05-08-2021(online)].pdf 2021-08-05
17 201847027122-FER.pdf 2021-10-17
18 201847027122-OTHERS [01-11-2021(online)].pdf 2021-11-01
19 201847027122-FORM 3 [01-11-2021(online)].pdf 2021-11-01
20 201847027122-FER_SER_REPLY [01-11-2021(online)].pdf 2021-11-01
21 201847027122-CLAIMS [01-11-2021(online)].pdf 2021-11-01
22 201847027122-US(14)-HearingNotice-(HearingDate-25-08-2022).pdf 2022-07-25
23 201847027122-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [19-08-2022(online)].pdf 2022-08-19
24 201847027122-US(14)-ExtendedHearingNotice-(HearingDate-26-09-2022).pdf 2022-08-24
25 201847027122-Information under section 8(2) [20-09-2022(online)].pdf 2022-09-20
26 201847027122-REQUEST FOR ADJOURNMENT OF HEARING UNDER RULE 129A [21-09-2022(online)].pdf 2022-09-21
27 201847027122-US(14)-ExtendedHearingNotice-(HearingDate-31-10-2022).pdf 2022-09-26
28 201847027122-Correspondence to notify the Controller [20-10-2022(online)].pdf 2022-10-20
29 201847027122-Written submissions and relevant documents [15-11-2022(online)].pdf 2022-11-15
30 201847027122-Retyped Pages under Rule 14(1) [15-11-2022(online)].pdf 2022-11-15
31 201847027122-FORM 3 [15-11-2022(online)].pdf 2022-11-15
32 201847027122-Annexure [15-11-2022(online)].pdf 2022-11-15
33 201847027122-2. Marked Copy under Rule 14(2) [15-11-2022(online)].pdf 2022-11-15
34 201847027122-PatentCertificate16-11-2022.pdf 2022-11-16
35 201847027122-IntimationOfGrant16-11-2022.pdf 2022-11-16

Search Strategy

1 SEARCHSTRATEGY1E_03-02-2021.pdf

ERegister / Renewals

3rd: 10 Jan 2023

From 16/12/2018 - To 16/12/2019

4th: 10 Jan 2023

From 16/12/2019 - To 16/12/2020

5th: 10 Jan 2023

From 16/12/2020 - To 16/12/2021

6th: 10 Jan 2023

From 16/12/2021 - To 16/12/2022

7th: 10 Jan 2023

From 16/12/2022 - To 16/12/2023

8th: 08 Nov 2023

From 16/12/2023 - To 16/12/2024

9th: 14 Nov 2024

From 16/12/2024 - To 16/12/2025